Ascendis Pharma AS ADR (ASND)

Currency in USD
255.96
-14.37(-5.32%)
Closed·
254.82-1.14(-0.45%)
·
Advertisement
ASND is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
254.03271.45
52 wk Range
188.08282.15
Key Statistics
Prev. Close
270.33
Open
269.76
Day's Range
254.03-271.45
52 wk Range
188.08-282.15
Volume
956.79K
Average Volume (3m)
743.52K
1-Year Change
20.6505%
Book Value / Share
25.88
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ASND Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
314.66
Upside
+22.93%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Ascendis Pharma AS ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

20 Buy
1 Hold
0 Sell
Ratings:
21 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 314.66
(+22.93% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jefferies
Buy300.00+17.21%-Maintain17/11/2026
Barclays
Buy341.00+33.22%329.00Maintain16/11/2026
TD Cowen
Buy352.00+37.52%341.00Maintain13/11/2026
Morgan Stanley
Buy302.00+17.99%273.00Maintain13/11/2026
UBS
Buy315.00+23.07%269.00Maintain13/11/2026

Ascendis Pharma AS ADR SWOT Analysis


Pipeline Promise
Ascendis Pharma's innovative therapies for rare endocrine disorders show potential, with Yorvipath exceeding expectations and a promising achondroplasia treatment in development.
Market Dominance
Explore Ascendis' first-mover advantage in hypoparathyroidism treatment, with Yorvipath projected to become a multi-billion euro drug in a market of 90,000 U.S. patients.
Financial Trajectory
Delve into Ascendis' projected revenue growth from €363.6 million in 2024 to €1.72 billion by 2027, with analysts expecting profitability by 2026.
Analyst Optimism
Learn about Wall Street's bullish stance on Ascendis, with price targets ranging from $170 to $250 and a highly favorable consensus rating of 1.25.
Read full SWOT analysis

Ascendis Pharma AS ADR Earnings Call Summary for Q3/2026

  • Ascendis beat Q3 2026 estimates with EPS of $1.08 vs. $0.80 expected; revenue rose 89% YoY to EUR 366M driven by rare-disease portfolio growth.
  • YORVIPATH revenue surged 103% YoY to EUR 291M; YUVIWEL doubled sequentially to EUR 16M in first full U.S. quarter with European launch pending.
  • Operating margin improved to 42% as expenses fell EUR 32M QoQ; company raised 2026 operating cash flow guidance to at least EUR 600M from EUR 189M in Q3.
  • Management reaffirmed long-term targets of EUR 5B revenue by 2030 and EUR 10B by 2035; plans to unveil new therapeutic area in 2027 supporting 2-3 products.
  • Stock rose 0.49% to $260.55 in premarket, near 52-week high; company continues EUR 400M buyback program with EUR 330M completed and 2M shares repurchased YTD.
Last Updated: 12/11/2026, 14:28
Read Full Transcript

Earnings

Latest Release
12/11/2026
EPS / Forecast
1.08 / 0.80
Revenue / Forecast
369.66M / 362.98M
EPS Revisions
Last 90 days

Compare ASND to Peers and Sector

Metrics to compare
ASND
Peers
Sector
Relationship
P/E Ratio
17.4x−2.7x−0.2x
PEG Ratio
0.04−0.090.00
Price/Book
10.2x2.0x2.6x
Price / LTM Sales
12.7x6.1x2.7x
Upside (Analyst Target)
23.2%128.8%69.6%
Fair Value Upside
Unlock10.5%11.7%Unlock

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
29.70M45.22%8.03B
Other Institutional Investors
38.45M54.78%10.39B
Public Companies & Retail Investors
0.000.00%0.00
Total
68.15M100.00%18.42B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
RA Capital Management, L.P.15.66%10,281,4962,779,397
T. Rowe Price Group, Inc.11.99%7,877,3752,129,491

People Also Watch

48.13
MXL
-2.83%
214.94
COHR
+0.99%
756.28
GEV
-2.06%
61.42
BMRN
-0.02%
460.33
HCA
-3.36%

FAQ

What Is the Ascendis Pharma AS ADR (NASDAQ: ASND) Share Price Today?

The Ascendis Pharma AS ADR stock price today is 255.96 USD.

What Stock Exchange Does Ascendis Pharma AS ADR (ASND) Trade On?

Ascendis Pharma AS ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Ascendis Pharma AS ADR?

The stock symbol (also called a 'ticker') for Ascendis Pharma AS ADR is "ASND."

What Is the Current Ascendis Pharma AS ADR Market Capitalisation?

As of today, Ascendis Pharma AS ADR (NASDAQ: ASND) market cap is 17.73B USD.

What Is Ascendis Pharma AS ADR's (ASND) Earnings Per Share (TTM)?

The Ascendis Pharma AS ADR EPS is currently 15.70 (Trailing Twelve Months).

When Is the Next Ascendis Pharma AS ADR Earnings Date?

Ascendis Pharma AS ADR's next earnings report will be released on 17/02/2027.

Is ASND a Buy or Sell From a Technical Analyst Perspective?

Based on today's Ascendis Pharma AS ADR moving averages and other technical indicators, the daily buy/sell signal for ASND stock is Neutral.

How Many Times Has Ascendis Pharma AS ADR Stock Split?

Ascendis Pharma AS ADR has split 0 times. (See the ASND stock split history page for full effective split date and price information.)

How Many Employees Does Ascendis Pharma AS ADR Have?

Ascendis Pharma AS ADR has 1189 employees, based on their latest Companies House report.

What is the current trading status of Ascendis Pharma AS ADR (NASDAQ: ASND)?

As of 19/11/2026, Ascendis Pharma AS ADR (ASND) is trading at a share price of 255.96 USD, with a previous close of 270.33 USD. The stock has fluctuated within a day range of 254.03 USD to 271.45 USD, while its 52-week range spans from 188.08 USD to 282.15 USD.

What Is Ascendis Pharma AS ADR (ASND) Price Target According to Analysts?

The average 12-month price target for Ascendis Pharma AS ADR is 314.66 USD, with a high estimate of 353.03322733 USD and a low estimate of 271.71619695 USD. 20 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +22.93% Upside potential.

What Is the ASND Premarket Price?

ASND's last pre-market stock price is 269.09 USD. The pre-market share volume is 576.00, and the stock has decreased by -1.24, or -0.46%.

What Is the ASND After Hours Price?

ASND's last after hours stock price is 254.82 USD, the stock has decreased by -1.14, or -0.45%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.